All fields are required.

Close Appointment form

Management Team

Improving patient outcomes with innovative drug therapies.

Stuart Paul

President and Chief Executive Officer

Stuart Paul has served as our President and Chief Executive Officer and a member of Rockwell Medical’s Board of Directors since September 2018.

Mr. Paul has significant operating experience in the healthcare industry, with a successful track record of executing commercialization strategies both domestically and internationally throughout his 25-year career. Previously, Mr. Paul served as Corporate Officer and Vice President of Abbott Laboratories, where he facilitated integration of the Alere acquisition, while leading its largest global business unit with $600 million of revenues. From 2015 to 2017, Mr. Paul served as the Vice President and General Manager of Quest Diagnostics’ U.S. East Region, where he led the turnaround of laboratories, patient services and the commercial business.

From 2007 to 2013, Mr. Paul worked within private equity at Gambro AB, where he was responsible for leading and profitably expanding a variety of businesses, including its Asia-Pacific and Americas Renal therapeutics businesses. Following the successful exit and sale of Gambro AB to Baxter International, Mr. Paul led the integration of the combined Baxter-Gambro Renal business in Latin America, driving further synergies, revenue and profit growth.

Mr. Paul received his bachelor’s degree in chemistry from Duke University and his master’s in marketing and finance from the Kellogg School of Management at Northwestern University.

Angus Smith

Chief Financial Officer

Angus Smith has served as our Chief Financial Officer since November 2018 and is responsible for overseeing all financial operations and investor relations for the company.

From 2014 to 2018, Mr. Smith worked at Pernix Therapeutics, where he most recently served as Senior Vice President, Chief Business Officer and Principal Financial Officer. Prior to this role, he served as both Vice President of Business Development and Strategic Planning, and Vice President of M&A and Corporate Finance.

Mr. Smith started his career in healthcare investment banking, working for both Cantor Fitzgerald and Gleacher & Company. During his nearly decade-long tenure, Mr. Smith focused on providing strategic and financial advice to specialty pharmaceutical and healthcare companies. Mr. Smith is a seasoned professional with expertise in debt and equity financings, mergers and acquisitions, licensing agreements, joint ventures and strategic partnerships.

Mr. Smith received his bachelor’s in mathematical economics from Colgate University.

Marc Hoffman, M.D.

Chief Medical Officer

Dr. Hoffman has served as Rockwell Medical’s Chief Medical Officer since November 2019. He has extensive experience in global drug development, medical affairs, pharmacovigilance and regulatory affairs, and has a proven track record in building, managing and globalizing medical teams for pharmaceutical companies; through both in-house roles at companies such as Baxter and Hospira and in senior leadership positions at various global contract research organizations (CROs), including Covance and, Parexel. Prior to joining Rockwell, Dr. Hoffman served as Chief Medical Officer at Celerion, Inc, a leader in early phase development and Patient iP, providing clinical leadership around Patient iP’s innovative platform, customer programs, and related medical affairs activities. Dr. Hoffman has also held the roles of Chief Medical Officer and Senior Vice President & General Manager over the Biopharmaceutical Business Unit at Theorem Clinical Research, leading the development of drugs and biologics.

Throughout his distinguished 30-year career, Dr. Hoffman has established medical capabilities in order to harness the data needed to develop and commercialize pharmaceutical products worldwide.

Dr Hoffman received his bachelor’s degree in psychology from Emory University and his MD from American University of the Caribbean. He went on to complete the Diploma in Pharmaceutical Medicine (DipPharmMed) organized jointly by BrAPP (British Association of Pharmaceutical Physicians) and Cardiff School of Pharmacy and Pharmaceutical Sciences, Cardiff University.

Ajay Gupta, M.D.

Chief Scientific Officer

Ajay Gupta, M.D., has served as our Chief Scientific Officer and a member of our Scientific Advisory Board since June 2009.

From 2002 to 2009, Dr. Gupta was an Associate Professor of Medicine at UCLA and Charles Drew University Schools of Medicine, where he had an active nephrology practice. He also served on the faculty at Washington University at St. Louis, State University of New York at Syracuse, University of Alabama at Birmingham and Henry Ford Hospital. Dr. Gupta maintains a nephrology practice and is a volunteer faculty member in the Division of Nephrology at University of California at Irvine.

Dr. Gupta is the inventor of delivering soluble ferric pyrophosphate parenterally including by slow continuous intravenous infusion, via the dialysate in hemodialysis and peritoneal dialysis patients, and as an additive to parenteral nutrition admixtures. He has several other patents for drugs, medical devices and diagnostic tests.

Dr. Gupta received a MBBS and completed his residency in internal medicine at AII India Institute of Medical Sciences in New Delhi, a clinical fellowship in Nephrology from Wayne State University and a research fellowship in Nephrology from Washington University at St. Louis. In addition, he is the founder of the Indian Society for Bone and Mineral Research.

Ray Pratt, M.D.

Chief Development Officer

Raymond D. Pratt, M.D., has served as Rockwell Medical’s Chief Development Officer since November 2019 and previously served as Chief Medical Officer since April 2012.

From 2003 to 2010, Dr. Pratt worked at Shire, where he served in various roles including Vice President of R&D, Scientific Leader of Emerging Business and Renal Business Units, Vice President of Global Clinical Medicine and Global Clinical Affairs and Head of U.S. Clinical Development. While at Shire, Dr. Pratt was instrumental in the FDA approval of Fosrenol ESRD indication and CKD non-dialysis indication in the European Union and United States. He has managed 10 different drugs through all stages of global development for renal and other indications and has extensive experience appearing before the FDA.

Prior to Shire, Dr. Pratt was Senior Director of Clinical Research and Development and Head of Central Nervous System and Internal Medicine Clinical Development at Eisai Medical Research for 9 years. He also previously served as an Assistant Professor at Johns Hopkins University and Cornell Medical College in the Department of Medicine and Nephrology, and as the Assistant Chief of Nephrology and Director of Dialysis Services at Walter Reed Army Medical Center.

Dr. Pratt received his M.D. from the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center.

Jim McCarthy

Senior Vice President of Business and Corporate Development

Jim McCarthy has served as our Senior Vice President of Business and Corporate Development since September 2018.

Mr. McCarthy is a seasoned business development executive with more than three decades of experience in the life sciences industry, including a 25-year career with Bristol-Myers Squibb. He has served in numerous roles assisting small and emerging life science companies in a wide-range of therapeutic areas with strategic and commercial planning, venture financing, commercial initiatives and deal support on a global basis. In addition, he has significant domestic and international corporate business development experience and has executed a broad range of transactions including licensing deals, strategic alliances and acquisitions.

Mr. McCarthy has also held leading roles in the Licensing Executive Society as Chair of the Life Sciences Sector, and with the Licensing Executive Society International Life Sciences Leadership Committee. He also is a recipient of the Licensing Executive Society “President’s Award.”

Mr. McCarthy received his bachelor’s in physical therapy from SUNY Upstate Medical Center and his MBA from Indiana University. He is also a recipient of the Certified Licensing Professional designation and is a U.S. Army Vietnam infantry veteran.

Anne Boardman

Vice President of Sales and Strategic Accounts

Anne Boardman has served as our Vice President of Sales and Strategic Accounts since joining the company in October 2018.

Ms. Boardman’s experience includes more than 30 years in renal, biotech and medical sales, sales management and large corporate account management. Additionally, Ms. Boardman has significant experience in the renal space, with a strong understanding of the renal provider and reimbursement landscape. Prior to joining Rockwell Medical, Ms. Boardman served as Director of Integrated Health Systems at Baxter Healthcare and Vice President of Strategic Accounts at Gambro AB.

Earlier in her career, Ms. Boardman worked at a variety of specialty pharmaceutical and healthcare companies including Genzyme Therapeutics, OrthoBiotech and Watson Nephrology.

Ms. Boardman received her bachelor’s from Rollins College.

Michael DeYoung

Vice President of Operations

Michael DeYoung has served as our Vice President of Operations since December 2018. Mr. DeYoung is responsible for leading Rockwell Medical’s Operations team, where he oversees manufacturing operations, logistics and company-wide strategy deployment, specifically for the launch of Triferic® in the U.S. and globally.

Mr. DeYoung’s experience includes more than 25 years in operations and finance. Before joining Rockwell Medical, he served as Chief Financial Officer of ZDHF Holdings, and as the Group Director of Moog Medical Device Group, where he was responsible for finance, human resources and IT operations, and played a key role in the turnaround of the division.

Mr. DeYoung also worked at Gambro AB, where he led operational initiatives contributing to the successful exit and sale of the company to Baxter International and was responsible for the full integration of the Baxter and Gambro renal operations in Latin America.

Mr. DeYoung received his bachelor’s in business management, general business from Western Michigan University and his master’s in accounting from Walsh College.